Apelin as a novel drug for treating preeclampsia

51Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.

Abstract

Preeclampsia is a pregnancy-specific disorder of new-onset hypertension and proteinuria after 20 weeks' gestation, often resulting in poor outcome. Previous studies demonstrated that apelin is an endogenous active peptide with visodilation and anti-oxidative stress capabilities. The present study investigated the effects of apelin in a rat model of preeclampsia induced by reduced uterine perfusion pressure (RUPP). Rats with RUPP displayed hypertension and poor pregnancy outcomes, such as decreased fetal and placental weight. Of note, apelin treatment significantly ameliorated the symptoms of preeclampsia, improved the impaired endothelial nitric oxide synthase/nitric oxide signaling and attenuated activation of oxidative stress in RUPP rats. Apelin may be a potential agent for preventing and treating preeclampsia.

Cite

CITATION STYLE

APA

Wang, C., Liu, X., Kong, D., Qin, X., Li, Y., Teng, X., & Huang, X. (2017). Apelin as a novel drug for treating preeclampsia. Experimental and Therapeutic Medicine, 14(6), 5917–5923. https://doi.org/10.3892/etm.2017.5304

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free